You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

MCL

Showing 1 - 25 of 788
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Myopia Trial in Singapore (Myopia Control Lens-1 (MCL1), Myopia Control Lens-2 (MCL2))

Not yet recruiting
  • Myopia
  • Myopia Control Lens-1 (MCL1)
  • Myopia Control Lens-2 (MCL2)
  • Singapore, Singapore
    Essilor R&D Centre Singapore
Nov 27, 2023

Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Houston (Biospecimen Collection, Follow-Up)

Recruiting
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Biospecimen Collection
  • Follow-Up
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Rituximab, Lenalidomide, Zebutinib ,Mantle Cell Lymphoma Trial in Hangzhou (ZR2 RDHAP)

Recruiting
  • Rituximab, Lenalidomide, Zebutinib ，Mantle Cell Lymphoma
  • ZR2 RDHAP
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Aug 8, 2023

DLBCL, MCL, and FL Patients Undergoing CAR Therapy

Not yet recruiting
  • Follicular Lymphoma
  • +2 more
  • ClonoSEQ
  • Palo Alto, California
    Stanford Cancer Center
Apr 19, 2022

Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma Trial in New York (Ibrutinib, Pembrolizumab)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Mantle Cell Lymphoma
  • New York, New York
    Icahn School of Medicine at Mount Sinai
Aug 22, 2022

Mantle Cell Lymphoma, Newly-diagnosed Mantle Cell Lymphoma Trial in Guangzhou (Zanubrutinib and Rituximab, R-DHAOx, Zanubrutinib

Recruiting
  • Mantle Cell Lymphoma
  • Newly-diagnosed Mantle Cell Lymphoma
  • Zanubrutinib and Rituximab
  • +2 more
  • Guangzhou, Guangdong, China
  • +2 more
May 6, 2022

Dementia With Lewy Bodies Using a Multimodal Approach

Not yet recruiting
  • Lewy Bodies Disease
  • +2 more
  • EEG
  • Paris, France
    Centre de neurologie Cognitive
Oct 4, 2023

Mantle Cell Lymphoma, Refractory Lymphoma Trial in Boston (Acalabrutinib, Venetoclax, Obinutuzumab)

Recruiting
  • Mantle Cell Lymphoma
  • Refractory Lymphoma
  • Boston, Massachusetts
  • +1 more
Aug 8, 2022

Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial (Routine care as per

Not yet recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • +5 more
  • Routine care as per site standard.
  • (no location specified)
Sep 15, 2023

Mantle Cell Lymphoma Trial in Busan (Ixazomib)

Recruiting
  • Mantle Cell Lymphoma
  • Busan, Western, Korea, Republic of
    Kosin University Gospel Hospital
Mar 31, 2022

Mantle Cell Lymphoma Trial in China (400mg of TQB3909 tablets, 600mg of TQB3909 tablets)

Recruiting
  • Mantle Cell Lymphoma
  • 400mg of TQB3909 tablets
  • 600mg of TQB3909 tablets
  • Beijing, Beijing, China
  • +27 more
Oct 26, 2023

Mantle Cell Lymphoma Trial in Houston (Ibrutinib)

Recruiting
  • Mantle Cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Nov 1, 2022

Aggressive B-Cell Non-Hodgkin's Lymphoma, Aggressive B-Cell NHL, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial

Not yet recruiting
  • Aggressive B-Cell Non-Hodgkin's Lymphoma
  • +4 more
  • (no location specified)
Dec 16, 2022

Mantle Cell Lymphoma Trial in Birmingham (Ublituximab, Umbralisib)

Recruiting
  • Mantle Cell Lymphoma
  • Birmingham, Alabama
    University of Alabama at Birmingham
Sep 8, 2021

Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma Trial (BGB-11417)

Not yet recruiting
  • Mantle Cell Lymphoma
  • +2 more
  • (no location specified)
Jul 25, 2022

Lymphoma, Mantle-Cell, Recurrent Lymphoma, Mantle-Cell Trial in United States (ABT-199 and Ibrutinib Combination)

Completed
  • Lymphoma, Mantle-Cell
  • Recurrent Lymphoma, Mantle-Cell
  • ABT-199 and Ibrutinib Combination
  • Duarte, California
  • +3 more
May 22, 2022

Mantle Cell Lymphoma (MCL) Trial in Australia, Canada, United States (Acalabrutinib, Venetoclax, Rituximab)

Not yet recruiting
  • Mantle Cell Lymphoma (MCL)
  • Duarte, California
  • +11 more
Jul 17, 2023

Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial in Beijing

Recruiting
  • Relapsed or Refractory B-cell Lymphoma
  • +6 more
  • Beijing, China
    Beijing Cancer Hospital
Feb 6, 2023

Chronic Lymphocytic Leukemia, Chronic Graft-versus-host-disease, Mantle Cell Lymphoma Trial in Poland (Acalabrutinib 2x100 MG

Recruiting
  • Chronic Lymphocytic Leukemia
  • +4 more
  • Acalabrutinib 2x100 MG Oral Capsule + alloSCT
  • Warszawa, Mazowieckie, Poland
  • +5 more
Dec 23, 2021

Mantle Cell Lymphoma Trial in Beijing (DTRMWXHS-12)

Active, not recruiting
  • Mantle Cell Lymphoma
  • Beijing, China
    Peking University Cancer Hospital
Aug 18, 2021

Mantle Cell Lymphoma Trial in New York (Acalabrutinib, Lenalidomide, Rituximab)

Recruiting
  • Mantle Cell Lymphoma
  • New York, New York
    Weill Cornell Medicine
Oct 29, 2021

Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy

Recruiting
  • DLBCL
  • +8 more
  • Cardiac MRI
  • Bonn, NRW, Germany
    University Hospital Bonn
Jun 11, 2022

Peripheral Arterial Disease, Iliac Artery Stenosis, Common Femoral Artery Stenosis Trial in Germany, Netherlands (Solaris

Recruiting
  • Peripheral Arterial Disease
  • +2 more
  • Solaris Vascular Stent Graft
  • Homburg, Germany
  • +7 more
Nov 14, 2022

Refractory Mantle Cell Lymphoma, Relapsed Mantle Cell Lymphoma Trial in China (Zanubrutinib)

Completed
Has Results
  • Refractory Mantle Cell Lymphoma
  • Relapsed Mantle Cell Lymphoma
  • Beijing, Beijing, China
  • +13 more
Oct 8, 2021

Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression, CD20 Positive Trial in Houston (Acalabrutinib, Venetoclax)

Recruiting
  • Blastoid Variant Mantle Cell Lymphoma
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022